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Background: About 3 – 5% of all patients with testicular germ cell tumour (GCT) develop a contralateral cancer,
the majority of which arise within 10–15 years. Little is known about the risk of second GCTs after more than two
decades. Here we present 3 cases with very late presenting contralateral GCT and provide a summary of similar
cases reported previously.
Case presentations: (1) This white Caucasian man underwent right-sided orchiectomy for a nonseminomatous
GCT at the age of 22 years. Additional treatment consisted of retroperitoneal lymph node dissection (RPLND) and
chemotherapy with 4 cycles of vinblastin / bleomycin. 36 years later, contralateral seminoma clinical stage 1 developed.
Cure was achieved by orchiectomy. Histologically, testicular intraepithelial neoplasia (TIN; intratubular germ cell
neoplasia) was detected in the tumour-surrounding tissue.
(2) This white Caucasian male had right-sided orchiectomy for nonseminomatous GCT at the age of 29 years.
Pathological stage 1 was confirmed by RPLND. 25 years later, he received left sided orchiectomy for seminoma
stage 1. Histologically, TIN was found in the tissue adjacent to seminoma. Two brothers had testicular GCT, too, one
with bilateral GCT. (3) This 21 year old white Caucasian man underwent left-sided orchiectomy for nonseminomatous
GCT. Pathological stage 1 was confirmed by RPLND. 21 years later, he received organ-preserving excision of a
right-sided seminoma, followed by BEP chemotherapy for stage 3 disease. Histologically, TIN was found in the
surrounding testicular tissue.
22 cases of bilateral GCT with intervals of 20 or more years have previously been reported, thereof three with
intervals of more than 30 years, the longest interval being 40 years.
Conclusion: Apart from increased risks of cardiovascular diseases and non-testicular malignancies, patients with
GCT face the specific probability of a second GCT in the long run. This risk persists life-long and is not eliminated
by chemotherapy. Contralateral testicular biopsy can identify patients at risk by revealing precursor cells of GCT
though false-negative biopsies may occur sporadically. However, in view of the multi-facetted late hazards of
GCT patients, this minor surgical procedure might somewhat simplify the long-time care of these patients.
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The phenomenon of malignant growths occurring in both
of the testicles has been known for more than a century.
Hamilton and Gilbert conducted the first systematic review
in 1942. Based on 144 cases collected from the literature
they opened their milestone article with the sentence:
“Testicular tumors possess a pronounced tendency to* Correspondence: DieckmannKP@t-online.de
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distribution, and reproduction in any mediumbilateralism” [1]. According to recent reviews, 3 – 5% of
patients with testicular germ cell tumour (GCT) develop
contralateral cancer which corresponds to a 20–30 fold
increased relative risk of tumour [2-4]. About 50% of these
events occur within 5 years after diagnosis of the primary
while 90% do so within a 10 years time-span [5]. Only few
more cancers arise thereafter. So far, little is known about
the risk of contralateral GCT after very long intervals
of more than two decades. All GCTs are preceded by a
common precursor named testicular intraepithelial
neoplasia (TIN; also called intratubular germ cell neoplasiatral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Grey scale ultrasonography of the testis with
colour-coded duplex imaging. Note the hypo-echoic nodule
at the cranial pole of the testis. Positive colour coded duplex
signals indicate vascularisation of the tumour. Histologically,
this tumour consisted of pure seminoma.
Figure 2 Histologic section, patient #1. typical histologic
features of seminoma. Note TIN (intratubular germ cell neoplasia)
in a seminiferous tubule (right side of picture). Hematoxylin eosin
stain; magnification according to scale-bar.
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the testicle many years before the clinical manifestation
of GCT [6,7]. To identify candidates for second GCTs,
contralateral testicular biopsy at the time of orchiectomy
of the primary is available [8,9]. However, physicians caring
for patients with GCT have widely remained disinclined to
this pro-active method of early detection of GCT [10].
Thus clinically, the risk of bilateral testicular tumour needs
to be considered during follow-up of patients with GCT.
Importantly, as this event may occur beyond the usual
5-years time-span of oncological follow-up, extended
observation time is required.
Here we present three cases with exceptionally late
onset of second GCT and we provide a survey of the
literature regarding the problem of very long intervals
between metachronous bilateral testicular tumours.
Case presentations
Case #1
This Caucasian white male underwent right-sided orchiec-
tomy for a nonseminomatous testicular GCT at the age of
22 years. History was uneventful; in particular there was
neither history of undescended testis nor any prior familial
events of testis cancer. Bulky retroperitoneal lymph-node
metastases were resected by extended retroperitoneal lymph
node dissection (RPLND) followed by four cycles of
chemotherapy. As cisplatin was not yet available at that
time (1976), the patient received treatment with the
contemporary Samuels regimen consisting of vinblastin
and bleomycin [11]. Possibly as a sequel of transfusion
therapy during multi-modal treatment for GCT, a viral
hepatitis B infection was diagnosed one year thereafter.
This infection entered a chronic non-aggressive course
and the patient stayed disease-free with respect to testicular
cancer for 36 years.
At the age of 58 years, he sought urological advice for
an increase of his prostate specific antigen (PSA) level to
1.5 ng/ml. The patient reported no specific symptoms
with regard to scrotal disorders. Upon physical examination
a firm nodule of about 1 cm in diameter was detected in
the left testicle. Serum tumour markers beta Human
chorionic gonadotropin (beta HCG), alpha fetoprotein
(AFP) and lactic dehydrogenase (LDH) were within normal
limits. Scrotal ultrasonography (Figure 1) and magnetic
resonance imaging (MRI) revealed a mass of 1.3 cm in
diameter within the testicle. As the testicle was small and
atrophic, left sided orchiectomy was performed and no
attempt of testis-sparing surgery was made. Histological
work-up disclosed pure seminoma with vascular invasion
but no infiltration of the rete testis. In the seminiferous
tubules surrounding the tumour abundant TIN was
detected (Figure 2). No metastases were detected, so the
patient was placed on a surveillance strategy according
to clinical stage I disease. Testosterone substitution isaccomplished by periodic intramuscular injections. One
year thereafter, the patient is well and without signs of
tumour recurrence.
Case #2
This white Caucasian man underwent right sided orchiec-
tomy for a testicular teratocarcinoma at the age of 29 years.
Pathological stage I was ascertained by RPLND. No further
therapy was instituted. After 25 years when aged 54 years,
the patient discovered a nodule in his remaining testicle
by self-palpation. Imaging procedures including ultrason-
ography, elastography and MRI disclosed a 1.5 cm mass in
the testicle. Serum tumour markers beta HCG, AFP
and LDH were not increased. As preoperative hormone
analysis had revealed a hypogonadal situation with
subnormal testosterone level and increased luteinizing
Table 1 Sequential bilateral testicular germ-cell tumours
with interval of 20 years or more










40 yrs 40 S S Philipsen [16] 1994
36 yrs 22 NS S Present case I 2013
32 yrs 26 S NS Scheiber [17] 1987
31 yrs 31 n.a. S Fukuhara [18] 2005
29 yrs 32 NS S Manny [19] 1999
28 yrs n.a. NS n.a. Andreassen [13] 2011
26 yrs 35 NS NS Hoekstra [20] 1982
25 yrs 46 n.a. S Melicow [21] 1955
25 yrs 25 S S Aristizabal [22] 1978
25 yrs 42 S S Ohyama [23] 2002
25 yrs 29 NS S Klatte [24] 2008
25 yrs 25 NS S Present case II 2013
24 yrs n.a. n.a. n.a. Schaapveld [3] 2012
23 yrs n.a. S* S* Hamilton [1] 1942
23 yrs 23 S S Kratzik [14] 1991
22 yrs n.a. S S Fergusson [25] 1962
22 yrs 32 S S Yoshida [26] 1981
22 yrs 22 n.a. NS Bach [27] 1983
22 yrs 39 S S Celebi [28] 1995
22 yrs n.a. n.a. n.a. Albers [29] 1999
21 yrs 17 S S Tekin [30] 2000
21 yrs 21 NS S Present case III 2013
20 yrs n.a. NS S Oesterlind [31] 1987
20 yrs 28 NS S Dieckmann [32] 1989
20 yrs n.a. n.a. n.a. Theodore [12] 2004
S seminoma; NS nonseminoma; n.a. not available.
*most probable histology, assumed from text.
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a testis-sparing procedure. Instead, a typical inguinal
orchiectomy with insertion of a testicular prosthesis was
carried out. Histologically, a classical seminoma was
identified, with wide areas of TIN in the surrounding
tissue. Chest and abdominal CT scans did not reveal
metastases. No further treatment was instituted except
for hormone replacement therapy. Follow-up of 12 months
so far is uneventful. Family history is of particular note:
The off-spring consists of one sister and six brothers, two
of whom were also struck by testicular cancer. A younger
brother succumbed to testicular choriocarcinoma at
the age of 23 years. One older brother survived bilateral
testicular cancer at ages 23 and 36 years.
Case #3
This white Caucasian patient underwent left-sided orchi-
ectomy along with a contralateral biopsy for a testicular
teratocarcinoma at the age of 21 years. Histologically,
the contralateral biopsy was without evidence of TIN.
History was uneventful; in particular there was neither
history of undescended testis nor any prior familial events
of testis cancer. RPLND revealed pathological stage I.
Thus, no systemic treatment was applied. At the age of
42 years, he presented with right-sided flank pain.
Magnetic resonance imaging revealed dilatation of the
right ureter caused by a huge retroperitoneal mass extend-
ing from the renal hilum into the pelvis. Beta HCG was
slightly increased to 11.9 U/l (reference <1.0 U/l), as was
LDH with 400 U/l (reference < 250 U/l), while AFP was
within normal limits. Scrotal ultrasonography revealed
a mass of 1.9 cm in diameter in the testicle. Organ pre-
serving surgery was performed along with additional
biopsies of the adjacent testicular parenchyma. Histological
work-up revealed pure seminoma with abundant TIN in
the surrounding tissue. Mediastinal lymphadenopathy in
addition to retroperitoneal metastases indicated stage III
disease with good prognosis according to IGCCCG. The
patient was rendered disease-free by systemic therapy with
three cycles of cisplatin, etoposide and bleomycin (BEP).
Two years thereafter, the patient is relapse-free and well.
Conclusions
There are at least four lessons to be learnt from these three
cases:
(1)The risk of second (contralateral) cancer in GCT
patients is pending life-long.
(2)Chemotherapy does not prevent a second testicular
tumour.
(3)Familial clustering of testicular cancer appears to be
associated with bilateral disease.
(4)Second tumours may arise despite a contralateral
biopsy negative for TIN.According to the most recent review, about 50% of all
contralateral testicular tumours arise later than 5 years
or more after the primary [2]. In a French analysis, 23%
of second tumours occurred between the 10th and the
20th year of follow-up [12], while no case developed later.
All of the major investigations on bilateral testicular
tumours accord with the contention, that the risk is
high during the first ten years and that it is gradually
decreasing thereafter forming an asymptotical curve
approaching the zero line of risk beyond the 20 years
mark [5,13-15]. As a matter of fact, this understanding
implicates the sporadic occurrence of such tumours at
exceptionally late time points. Accordingly, Table 1 provides
a synopsis of 25 cases of the literature (including the
present cases) with bilateral testicular germ cell tumours
occurring after 20 or more years [1,3,12-14,16-32]. It is of
note that already Hamilton and Gilbert in their 1942
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a scholarly review on testicular new growths did so in
1955 [21]. The longest interval ever reported is 40 years
in a Danish man [16]. The present case (#1) is ranking
second on this list with an interval of 36 years.
The median age at primary presentation of the patients
with very late presenting contralateral testicular tumour is
28.5 years that is not at variance with the over-all median
age of patients with germ cell cancer [33]. Yet, there
appears to be a slight deviation from the contention that
patients with bilateral tumours usually experience a rather
early presentation of their primary [12,34,35]. All of our
cases had a nonseminomatous histology at first presenta-
tion which is somehow at variance with the preponderance
of seminoma usually encountered in cases with bilateral
testicular GCT [36]. Table 1 does not suggest any asso-
ciation of histology with the particular risk of late second
GCT. Little is known about clinical stage at primary diag-
nosis and during relapse for these particular patients.
In most of the reports (Table 1) information on clinical
staging is not provided. In our series, only one had metas-
tasized disease at primary presentation while two had
stage I disease. So, the basic message of this compilation
of cases is the information that the risk of contralateral
testicular cancer will persist life-long.
(2) Our first case experienced his second tumour despite
interval chemotherapy. Pathogenetically, all GCTs are
preceded by the premalignant lesion TIN (ITGCNU) that
is believed to be present in the contralateral testicle
already at the time of the first tumour. Concerns regarding
the low sensitivity of chemotherapy to eradicate the
precursor in the contralateral gonad had been raised
already in the 1980ies [37]. Accordingly, large series of
patients with bilateral testicular tumours clearly revealed
that chemotherapy does not protect against second
tumours [4,15]. In the largest investigation of bilateral
tumours performed on the SEER data base, 39 second
tumours (> 1%) were found among 3157 nonseminoma
patients receiving chemotherapy [35]. Recently, it was
shown that low doses of two cycles of cisplatin-based
chemotherapy are probably without any considerable
effect on TIN, three or more cycles may eradicate it in
about 75% of cases [38]. Our patient had received 4 cycles
of chemotherapy, however, that treatment did not involve
cisplatin, which clearly is the most efficacious drug.
So, one might speculate that the vinblastin/bleomycin
regimen could have suppressed TIN only temporarily .
Accordingly, it took 36 years for the remaining TIN cells
to recover and to finally progress to invasive seminoma.
In fact, there is some indication of extended intervals in
bilateral GCTs following chemotherapy [13,15]. Our
patient apparently represents the case with the longest
lag time between sequential bilateral testicular tumours
and interval chemotherapy. So, this case represents anexceptional example showing the low efficacy of chemo-
therapy to prevent sequential testicular neoplasms.
(3) Two brothers of case #2 had suffered from testicular
cancer, too, one of whom had even bilateral disease.
Approximately 1-3% of all patients with testicular GCT
have close relatives with the same diagnosis [34]. Notably,
6-15% of all familial cases of GCT develop bilateral disease
while second GCTs occur in only 3-5% among sporadic
cases [39]. Accordingly, a strong hereditary predisposition
of testicular GCT is assumed [40]. While the clinical
evidence for the involvement of genetic factors in the
etiology of GCT is undisputed, the assumed Testicular
GCT 1 gene has so far not been identified [41]. From a
practical point of view, it is concluded that history of
familial testicular cancer should increase the clinician´s
vigilance regarding the possible development of contra-
lateral cancer. As elucidated by the case, this event may
even occur after a very long lag time.
(4) In one of our patients (#3), contralateral GCT devel-
oped despite a previous testicular biopsy negative for TIN.
False-negative biopsies do occur in less than 10% of cases
[8]. Multiple probing has been recommended to reduce
the rate of biopsy-failures. In fact, systematic two-site
biopsies revealed an 18% extra yield of contralateral TIN
[8]. Whether or not double biopsy would have disclosed
the true diagnosis at that time remains elusive, but clearly,
multiple biopsies are more sensitive than a single one.
Our three cases highlight one of the manifold problems
in the long-time follow-up of patients with testicular GCT.
The specific risk of a second testicular tumour is one threat
in addition to the well-recognized hazards of metabolic
disorders, cardiovascular diseases and non-testicular malig-
nancies [42]. The risk of contralateral GCT is not elimi-
nated by chemotherapy. As all of our patients had TIN in
the tumour-surrounding tissue, histologically, a contralat-
eral biopsy at the time of the primary might have identified
the impending second tumour. Although not explicitly
recommended by current guide-lines [43-45], contralateral
testicular biopsy is clearly valuable for exploring the
particular risk of second testicular cancer [8,46].
Consent
Written informed consent was obtained from all of the
three patients for publication of these Case reports and the
two accompanying images. A copy of the written consent
is available for review by the Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KPD conceived and designed the study, analyzed the clinical data, and
drafted the manuscript. PA performed the ultrasonographic examinations of
the patients, participated in the clinical management of cases, participated in
designing and of the report and drafting of the manuscript. FS carried out
the histological examinations, participated in designing the report. TK
Dieckmann et al. BMC Urology 2013, 13:71 Page 5 of 6
http://www.biomedcentral.com/1471-2490/13/71participated in the designing of the study, carried out much of the clinical
management of the cases, helped analyzing the clinical data. CM
participated in the designing of the study, accumulated and abstracted the
clinical data, helped in clinical management of the cases. CR conceived the
study, participated in designing the report, analyzed the clinical data, and
drafted the manuscript. All authors read and approved the final manuscript.
Acknowledgement
This study was supported by the German Ministry of Defence.
Author details
1Klinik für Urologie, Albertinen-Krankenhaus Hamburg, Suentelstr. 11a,
D-22457 Hamburg, Germany. 2Institut für Hämatopathologie,
Fangdieckstrasse 75a, D-22547 Hamburg, Germany. 3Praxis für Urologie,
Rosengarten 5, D-22880 Wedel, Holstein, Germany. 4Bundeswehrkrankenhaus
Hamburg, Abteilung für Urologie, Lesserstrasse 180, D-22049 Hamburg,
Germany.
Received: 7 July 2013 Accepted: 4 December 2013
Published: 9 December 2013
References
1. Hamilton JB, Gilbert JB: Studies in malignant tumors of the testis. IV.
Bilateral testicular cancer. Incidence, nature, and bearing upon
management of the patient with a single testicular cancer. Cancer Res
1942, 2:125–129.
2. Zequi SD, da Costa WH, Santana TB, Favaretto RL, Sacomani CA, Guimaraes
GC: Bilateral testicular germ cell tumours: a systematic review. BJU Int
2012, 110(8):1102–1109.
3. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, de Wit R, Horenblas
S, Witjes JA, Hoekstra HJ, Kiemeney LA, Louwman WJ, Ouwens GM, et al:
Risk and prognostic significance of metachronous contralateral testicular
germ cell tumours. Br J Cancer 2012, 107(9):1637–1643.
4. Hoff Wanderas E, Fossa SD, Tretli S: Risk of a second germ cell cancer after
treatment of a primary germ cell cancer in 2201 Norwegian male
patients. Eur J Cancer 1997, 33(2):244–252.
5. Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW: Bilateral
testicular germ cell tumors, Report of nine cases and review of the
literature. Cancer 1986, 57(6):1254–1258.
6. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE: Carcinoma
in situ testis, the progenitor of testicular germ cell tumours: a clinical
review. Ann Oncol 2005, 16:863–868.
7. Dieckmann KP, Loy V, Huland H: Das Carcinoma in situ des Hodens:
klinische Bedeutung, Diagnose und Therapie. Urologe A 1989, 28:271–280.
8. Dieckmann KP, Kulejewski M, Heinemann V, Loy V: Testicular biopsy for
early cancer detection - objectives, technique and controversies.
Int J Androl 2011, 34(4 Pt 2):e7–e13.
9. Dohle GR, Elzanaty S, van Casteren NJ: Testicular biopsy: clinical practice
and interpretation. Asian J Androl 2012, 14(1):88–93.
10. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R,
Cavallin-Stahl E, Clarke NW, Claßen J, et al: Maintaining success, reducing
treatment burden, focusing on survivorship: highlights from the third
European consensus conference on diagnosis and treatment of
germ-cell cancer. Ann Oncol 2012, 24(4):878–888.
11. Samuels ML, Lanzotti VJ, Holoye PY, Boyle LE, Smith TL, Johnson DE:
Combination chemotherapy in germinal cell tumors. Cancer Treat Rev
1976, 3(4):185–204.
12. Theodore C, Terrier-Lacombe MJ, Laplanche A, Benoit G, Fizazi K, Stamerra
O, Wibault P: Bilateral germ-cell tumours: 22-year experience at the
Institut Gustave Roussy. Br J Cancer 2004, 90:55–59.
13. Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fossa SD: Risk of
metachronous contralateral testicular germ cell tumors: a population-based
study of 7,102 Norwegian patients (1953–2007). Int J Cancer 2011,
129(12):2867–2874.
14. Kratzik C, Aiginger P, Kuber W, Riccabona M, Kuhrer I, Joos H, Frick J, Amann
G, Mayr W: Risk factors for bilateral testicular germ cell tumors.
Does heredity play a role? Cancer 1991, 68(4):916–921.
15. Geczi L, Gomez F, Bak M, Bodrogi I: The incidence, prognosis, clinical and
histological characteristics, treatment, and outcome of patients with
bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol
2003, 129:309–315.16. Philipsen JP, Gimbel HM: Cancer of the testis in an 80 year old man with
a former contralateral testicular cancer. (in Danish). Ugeskr Laeger 1994,
156:2908–2909.
17. Scheiber K, Ackermann D, Studer UE: Bilateral testicular germ cell tumors:
a report of 20 cases. J Urol 1987, 138:73–76.
18. Fukuhara Y, Shiga Y, Ken S: [Bilateral testicular tumors recurring 31 years
after the initial treatment: a case report and the literature review][Article
in Japanese]. Nippon Hinyokika Gakkai Zasshi 2005, 96:17–20.
19. Manny HP, Thon WF, Brüschke C, Ostertag H: Spätes Auftreten eines
metachronen bilateralen Hodentumors und eines keimzellunabhängigen
Zweittumors. Akt Urol 1999, 30:422–425.
20. Hoekstra HJ, Wobbes T, Sleyfer DT, Schraffordt Koops H: Bilateral primary
germ cell tumors of testis. Urology 1982, 19(2):152–154.
21. Melicow MM: Classification of tumors of testis: a clinical and pathological
study based on 105 primary and 13 secondary cases in adults, and
3 primary and 4 secondary cases in children. J Urol 1955,
73(3):547–574.
22. Aristizabal S, Davis JR, Miller RC, Moore MJ, Boone ML: Bilateral primary
germ cell testicular tumors: report of four cases and review of the
literature. Cancer 1978, 42(2):591–597.
23. Ohyama C, Kyan A, Satoh M, Saito S, Nishimura Y, Imai Y, Oikawa K,
Yokoyama J, Suzuki K, Takeuchi M, et al: Bilateral testicular tumors: a
report of nine cases with long-term follow-up. Int J Urol 2002,
9(3):173–177.
24. Klatte T, de Martino M, Arensmeier K, Reiher F, Allhoff EP, Klatte D:
Management and outcome of bilateral testicular germ cell tumors: a
25-year single center experience. Int J Urol 2008, 15(9):821–826.
25. Fergusson JD: Tumours of the testis. Brit J Urol 1962, 34:407–421.
26. Yoshida M, Machida T, Masuda F, Miki M, Ohishi Y, Ueda M, Yanagisawa M,
Tanino M, Kishimoto K, Kawaguchi Y: [Five cases of bilateral testicular
tumors: a review of 118 cases in Japanese literature (author's transl)].
[Article in Japanese]. Nihon Hinyokika Gakkai Zasshi 1981, 72(4):460–472.
27. Bach DW, Weissbach L, Hartlapp JH: Bilateral testicular tumor. J Urol 1983,
129(5):989–991.
28. Celebi I, Tekgül S, Ozen HA, Ozgü I, Remzi D: Sequential bilateral germ cell
tumours of the testis. Int Urol Nephrol 1995, 27(2):183–187.
29. Albers P, Goll A, Bierhoff E, Schoeneich G, Müller SC: Clinical course and
histopathologic risk factor assessment in patients with bilateral testicular
germ cell tumors. Urology 1999, 54:714–718.
30. Tekin A, Aygun YC, Aki FT, Ozen H: Bilateral germ cell cancer of the testis:
a report of 11 patients with a long-term follow-up. BJU Int 2000,
85:864–868.
31. Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen
B, Munck Hansen J, Rasmussen LH: Risk of bilateral testicular germ cell
cancer in Denmark: 1960–1984. J Natl Cancer Inst 1991, 83(19):1391–1395.
32. Dieckmann KP, Düe W, Klän R: Bilateraler Hodentumor nach Intervall von
20 Jahren. Med Welt 1989, 40:75–76.
33. Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP: Changes
in epidemiologic features of testicular germ cell cancer: age at diagnosis and
relative frequency of seminoma are constantly and significantly increasing.
Urol Oncol 2013. doi: 10.1016/j.urolonc.2012.12.002. [Epub ahead of print].
34. Nicholson PW, Harland SJ: Inheritance and testicular cancer. Br J Cancer
1995, 71:421–426.
35. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, Travis
LB: Risk of contralateral testicular cancer: a population-based study of
29,515 U.S. men. J Natl Cancer Inst 2005, 97:1056–1066.
36. Thomas JP, Davis-Dao C, Lewinger JP, Siegmund KD, Hamilton AS, Daneshmand
S, Skinner EC, Thomas DC, Cortessis VK: Null association between histology of
first and second primary malignancies in men with bilateral testicular germ
cell tumors. Am J Epidemiol 2013, 178(8):1240–1245.
37. Bottomley D, Fisher C, Hendry WF, Horwich A: Persistent carcinoma in situ
of the testis after chemotherapy for advanced testicular germ cell
tumours. Br J Urol 1990, 66(4):420–424.
38. Dieckmann KP, Wilken S, Loy V, Matthies C, Kleinschmidt K, Bedke J,
Martinschek A, Souchon R, Pichlmeier U, Kliesch S: Treatment of testicular
testicular neoplasia (intratubular germ cell neoplasia unspecified) with
local radiotherapy or with platinum-based chemotherapy: a survey of
the German Testicular Cancer Study Group. Ann Oncol 2013,
24(5):1332–1337.
39. Mai PL, Friedlander M, Tucker K, Phillips KA, Hogg D, Jewett MA, Lohynska R,
Daugaard G, Richard S, Bonaïti-Pellié C, The International Testicular Cancer
Dieckmann et al. BMC Urology 2013, 13:71 Page 6 of 6
http://www.biomedcentral.com/1471-2490/13/71Linkage Consortium, et al: A clinicopathologic descriptive analysis of 461
familial malignant testicular germ cell tumor kindred. Urol Oncol 2010,
28(5):492–499.
40. Hemminki K, Li X: Familial risk in testicular cancer as a clue to a heritable
and environmental aetiology. Br J Cancer 2004, 90:1765–1770.
41. Kratz CP, Mai PL, Greene MH: Familial testicular germ cell tumours. Best
Pract Res Clin Endocrinol Metab 2010, 24(3):503–513.
42. Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ,
Schmoll HJ, Sternberg CN: Sequelae of treatment in long-term survivors
of testis cancer. Eur Urol 2011, 60(3):516–526.
43. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K,
Horwich A, Laguna MP: EAU guidelines on testicular cancer: 2011 update.
Eur Urol 2011, 60(2):304–319.
44. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK,
Carducci MA, Chang SS, Choueiri TK, Gupta S, et al: Testicular cancer.
J Natl Compr Canc Netw 2012, 10(4):502–535.
45. Howard GC, Nairn M, on behalf of the Guideline Development Group:
Management of adult testicular germ cell tumours: summary of updated
SIGN guideline. BMJ 2011, 342:d2005.
46. Rud CN, Daugaard G, Rajpert-De Meyts E, Skakkebæk NE, Petersen JH,
Jørgensen N: Sperm concentration, testicular volume and age predict risk
of carcinoma-in-situ in contralateral testis of men with testicular germ-cell
cancer. J Urol 2013, 190(6):2074–2080.
doi:10.1186/1471-2490-13-71
Cite this article as: Dieckmann et al.: Sequential bilateral testicular
tumours presenting with intervals of 20 years and more. BMC Urology
2013 13:71.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
